CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS ( MICROCÍTICO ) . La Estadificación Determina el Tratamiento y los Eventos Adversos .
Las Pautas Actuales de la Red Nacional Integral del Cáncer (NCCN) Para el Tratamiento del Cáncer de Pulmón de Células Pequeñas en ESTADIO LIMITADO ... Y Del Cáncer de Pulmón de Células Pequeñas en ESTADIO AVANZADO :
*.- Limited-Stage Small Cell Lung Cancer :
The CURRENT NATIONAL COMPREHENSIVE CANCER NETWORK ( NCCN ) GUIDELINES For Patients With LIMITED-STAGE SCLC ( Meaning That it is STAGE I-III ) is To Treat With RADIATION and CHEMOTHERAPY With Curative Intent .
“If it is a Patient with LIMITED-STAGE DISEASE, and they’re Receiving CISPLATIN — which is typically the STANDAR in Addition to ETOPÓSIDE — The Nephrotoxicity that comes with the Drug is Really Important To Manage,” Sullivan Explained . ...
** Extensive-Stage Small Cell Lung Cancer :
EXTENSIVE-STAGE ( STAGE IV ) SCLC, on the other hand, is a disease that has spread outside the bounds of 1 RADIATION field, and therefore, Cure May Not Be an Optión . For These Patients, the Goal is To Control Symptoms and prolong life, according to the NCCN GUIDELINES .
For this Patient population, the NCCN GUIDELINES Recommend Treatment with dual CHEMOTHERAPY ( CARBOPLATIN or CISPLATIN WITH ETOPÓSIDE ) Plus a Checkpoint Inhibitor ( ATEZOLIZUMAB [ TECENTRIQ ] or DURVALUMAB [ IMFINZI ) ), Followed by MAINTENANCE THERAPY With The Checkpoint Inhibitor . ...
*** Newer Treatment Options For Extensive-Stage Disease :
More Recently, The FDA APPROVED TARLATAMAB-DLLE ( IMDELLTRA ) For EXTENSIVE-STAGE SCLC That Progressed on or After PLATINUM-BASED CHEMOTHERAPY . This DRUG is a BISPECIFIC T-CELL Engager That TARGETS DLL3 .
“Now To See an APPROVED TREATMENT For These Patients is Really Exciting,” Sullivan said . “In addition to that, there are clinical trials that are really testing a lot of these novel agents to see if there are any benefit that is available for these patients that might not already be on the market or might be better than what is on the market .” ...
